Suchergebnisse - BAN2401

1

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials

von: Yue Qiao

2023, in: Frontiers in Aging Neuroscience

Wird geladen...
2

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

von: Logovinsky, Veronika

2016, in: Alzheimer's research & therapy

Wird geladen...
3

Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy.

von: Jacopo C. DiFrancesco

2015, in: Frontiers in Neurology

Wird geladen...
4

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

von: Swanson, Chad J.

2021, in: Alzheimer's research & therapy

Wird geladen...
5

Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease

von: Md. Sahab Uddin

2020, in: International Journal of Molecular Sciences

Wird geladen...
6

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

von: Tolar, Martin

2020, in: Alzheimer's research & therapy

Wird geladen...
7

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

von: Chad J. Swanson

2021, in: Alzheimer’s Research & Therapy

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!